AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33835936
Drug: Email-based dialectical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Email-based dialectical behavioral therapy (DBT)
Trial: 33835936
Drug: In-person dialectical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person dialectical behavioral therapy (DBT)
Trial: 33836153
Drug: Serious treatment-related
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serious treatment-related adverse events
Trial: 33836153
Drug: Grade 3-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade 3-4 treatment-related events
Trial: 33836153
Drug: Common grade
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common grade 3-4 treatment-related events
Trial: 33836153
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of pembrolizumab
Trial: 33836262
Drug: No EVOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No EVOO treatment
Trial: 33836671
Drug: Weekly neurologist
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly neurologist consultations
Trial: 33837055
Drug: Belapectin (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belapectin (2, 4, or 8 mg/kg IV 60 min before pembrolizumab) + pembrolizumab (200 mg IV every 3 weeks for five cycles)
Trial: 33839074
Drug: ET-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET-directed therapy (monotherapy)
Trial: 33840050
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal
Trial: 33840068
Drug: 3-month community
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month community intervention consisting of group education for type 2 diabetes knowledge, diet, exercise in combination with usual diabetes care
Trial: 39538234
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly (AOM)
Trial: 33840725
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori eradication treatments
Trial: 33840725
Drug: Bismuth-based quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based quadruple therapy
Trial: 33840725
Drug: Longer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer treatment durations
Trial: 33841012
Drug: Korea Red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korea Red Ginseng (KRG) 2,000 mg/day for 30 days
Trial: 33842870
Drug: ASP0113 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP0113 (5 mg/mL, 1 mL, five injections)
Trial: 33842908
Drug: UNI91104 (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UNI91104 (inhaled and intranasal niclosamide)
Trial: 33843258
Drug: Consensus decision-making
RxNorm normalized name: Consensi
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consensus decision-making on continuation and regimen of preoperative antiplatelet therapy (APT)
Trial: 33843599
Drug: Web-based dialectical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based dialectical behavior therapy (DBT) skills site with secure message coaching; no specific dosage or duration mentioned.
Trial: 33844595
Drug: Pembrolizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (2 mg/kg or 200 mg every 3 weeks)
Trial: 33844623
Drug: 9vHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9vHPV vaccine (three doses: Day 1, Month 2, Month 6)
Trial: 33845032
Drug: Renin-Angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-Angiotensin system inhibitors (RASi)
Trial: 33845259
Drug: Post-transplantation bendamustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplantation bendamustine (PTB) at doses of 140 mg/m², 100 mg/m², and 70 mg/m²
Trial: 33845893
Drug: Short-term (ST)
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term (ST) metformin withdrawal
Trial: 33845893
Drug: Long-term (LT)
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term (LT) metformin withdrawal
Trial: 33845905
Drug: Dalpiciclib 100
RxNorm normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib 100 mg, 125 mg, and 150 mg
Trial: 33845905
Drug: Dalpiciclib 125
RxNorm normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib 125 mg and 150 mg cohorts
Trial: 33845905
Drug: Dalpiciclib 150
RxNorm normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib 150 mg cohort
Trial: 33846719
Drug: Intermittent preventative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventative treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP)
Trial: 33846719
Drug: Malaria treatment
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malaria treatment after diagnosis alongside IPTp-SP
Trial: 33847257
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum retinol (LSR) defined as serum retinol ≤20 µg/dl
Trial: 33848093
Drug: Pediatric heat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric heat illness treatment
Trial: 33848199
Drug: Treatment-related changes
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related changes in left atrial structure, specific details not available.
Trial: 33848258
Drug: Surgical therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy, balloon pulmonary angioplasty, and medical therapy (details collected at enrollment and follow-up)
Trial: 33848258
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life surveys administered at enrollment and biannually
Trial: 33849625
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment limitations
Trial: 34741189
Drug: Treatment limitations
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment limitations
Trial: 33849625
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without treatment limitations
Trial: 33849625
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with treatment limitations
Trial: 33851477
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg p.o. b.i.d. for 14 days followed by imiquimod 5% cream topically to the most clinically active lesions 3 days a week for 28 days
Trial: 33852104
Drug: LY3022855 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022855 100 mg QW with durvalumab 750 mg Q2W
Trial: 33852104
Drug: LY3022855 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022855 50 or 100 mg QW with tremelimumab 75/225/750 mg Q4W
Trial: 33852104
Drug: LY3022855 25/50/75/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022855 25/50/75/100 mg QW with durvalumab 750 mg Q2W
Trial: 33852146
Drug: Low-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interleukin-2 (IL-2) treatment
Trial: 33853614
Drug: EMG-triggered NMES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG-triggered NMES in addition to robot therapy (hand group; n=10)
Trial: 33854484
Drug: Semaglutide (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide (once-weekly subcutaneously)
Trial: 33854484
Drug: Semaglutide (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide (once-daily orally)
Trial: 33854572
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks to week 96
Trial: 33854746
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two or three methods in treatment of CTEPH (specific methods not detailed in the abstract)
Trial: 33856003
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (high-dose repletion therapy) for eight weeks
Trial: 33856277
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg and escalating doses of lenalidomide on Days 1-7 with DA-EPOCH-R (Days 1-5) in 21-day cycles
Trial: 33856599
Drug: PEG-BCT-100 at
RxNorm normalized name: PEG-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-BCT-100 at 2.7 mg/kg weekly intravenous
Trial: 33857185
Drug: Inhaled sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sedation using volatile agents (Sevoflurane and Isoflurane) with the Anaesthetic Conserving Device (AnaConDa, Sedana Medical)
Trial: 33857185
Drug: Inhaled sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sedation
Trial: 33857917
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of e-CBT and medication
Trial: 33858040
Drug: Dasatinib combined
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib combined with multi-agent chemotherapy regimen
Trial: 33858202
Drug: Chemotherapy (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (adjuvant or neoadjuvant)
Trial: 33858486
Drug: Probiotic lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lozenges (2/day for 90 days)
Trial: 33858486
Drug: MTZ (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTZ (400 mg) and AMX (500 mg TID for 14 days)
Trial: 33858486
Drug: Probiotic lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lozenges and MTZ+AMX
Trial: 33859147
Drug: Expedited partner
RxNorm normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expedited partner treatment (EPT)
Trial: 33860280
Drug: Intra-operative infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-operative infusion of [U-13C] glucose
Trial: 33860864
Drug: Capacitive radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capacitive radiofrequency (BTL-6000 TR-Therapy Pro®) applied for 10 min with epidermal temperature above 40°C
Trial: 33860922
Drug: Adjunctive aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive aripiprazole treatment for 8 weeks
Trial: 33860922
Drug: Adjunctive aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive aripiprazole treatment
Trial: 33861204
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with pedometer and daily steps recorded in a diary
Trial: 33861210
Drug: SPARC intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SPARC intervention (Sex Workers Promoting Action, Risk Reduction, and Community Mobilization) drop-in center and mobile outreach program; services include harm reduction, reproductive health, sexual health care, medication-assisted treatment, legal aid, counseling, and distribution of harm reduction tools.
Trial: 33861486
Drug: Trametinib 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib 2.0 mg daily
Trial: 33863803
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity measured by hyperinsulinemic euglycemic clamp
Trial: 33863803
Drug: Insulin response
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin response in women who lost weight
Trial: 33863856
Drug: Olorinab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olorinab (3 or 30 mg/kg) administered twice daily by oral gavage for 5 days starting 1 day before colitis induction
Trial: 33863856
Drug: Olorinab (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olorinab (1, 3, 10, or 30 mg/kg) administered twice daily by oral gavage for 5 days starting 24 days after colitis induction
Trial: 33865150
Drug: Non-medical use
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-medical use (NMU) of drugs
Trial: 33865150
Drug: Psychostimulant medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychostimulant medications
Trial: 33865203
Drug: MEK inhibitor
RxNorm normalized name: Mitogen-activated protein kinase (MEK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK inhibitor (MEKi)
Trial: 33865434
Drug: Yimingjia adjunct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yimingjia adjunct therapy with desloratadine dry suspension
Trial: 33865434
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with desloratadine dry suspension
Trial: 33866531
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral sodium selenite (dosing regimens: 33 mg daily, 11 mg BID, 5.5 mg TID)
Trial: 33866662
Drug: Medication history
RxNorm normalized name: histolyn CYL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication history interview conducted by pharmacists
Trial: 33866662
Drug: Patients taking
RxNorm normalized name: Lamictal Blue (For Patients Taking Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients taking more than 5 medications
Trial: 33866662
Drug: Adverse drug
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse drug events (ADE) detected during the ED visit
Trial: 33866662
Drug: Medication-related variables
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-related variables associated with increased hospital admission
Trial: 33866938
Drug: Chemotherapy (single-agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (single-agent paclitaxel or doxorubicin)
Trial: 33867192
Drug: Lenvatinib (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (18 mg) plus everolimus (5 mg) orally once daily
Trial: 33867481
Drug: Muscadine grape
RxNorm normalized name: Muscadine Grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscadine grape extract (MGE) capsules by mouth twice daily, 320 to 1600 mg total phenolics/d for 4 weeks
Trial: 33868050
Drug: Imagery Rescripting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagery Rescripting and Schema Therapy
Trial: 33870151
Drug: TVB-2640 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVB-2640 (60 mg/m) as monotherapy
Trial: 33871807
Drug: Mongersen 160
RxNorm normalized name: Mongersen
DrugBank: Mongersen (DB15019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mongersen 160 mg/day for 12 weeks
Trial: 33871888
Drug: Double-positive for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-positive for LG3-A and donor-specific antibody (DSA)
Trial: 33872131
Drug: Silver nanoparticles
RxNorm normalized name: Silver nanoparticles
DrugBank: Silver (DB12965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver nanoparticles (exact dosage and duration not specified)
Trial: 33873093
Drug: Novel recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel recombinant five-antigen Staphylococcus aureus vaccine
Trial: 33874975
Drug: Oral Ty21a
RxNorm normalized name: Salmonella typhi Ty21a live antigen 2000000000 UNT [Vivotif]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ty21a immunization
Trial: 33875560
Drug: Bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy (BT; IV tissue plasminogen activator + EVT)
Trial: 33875611
Drug: PVSRIPO monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVSRIPO monotherapy (1, 2, or 3 injections with 21 days between injections)
Trial: 33875845
Drug: Intravenous olipudase
RxNorm normalized name: olipudase alfa
DrugBank: Olipudase alfa (DB12835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous olipudase alfa administered every 2 weeks with intrapatient dose escalation to 3 mg/kg
Trial: 33876222
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intravenous iron tracers administered before treatment and after intensive phase (8/12 weeks) and complete treatment (24 weeks)
Trial: 33876229
Drug: Maternal antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal antimicrobial treatment ≥1 day before delivery
Trial: 33876229
Drug: No maternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maternal antimicrobial treatment
Trial: 33876576
Drug: Pamiparib 60
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib 60 mg orally twice daily
Trial: 33877496
Drug: Football training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Football training (twice weekly for six months)
Trial: 38532458
Drug: Belumosudil 200
RxNorm normalized name: belumosudil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belumosudil 200 mg once daily
Trial: 33877856
Drug: Belumosudil 400
RxNorm normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belumosudil 400 mg once daily
Trial: 33877856
Drug: Corticosteroid (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (CS) treatment
Trial: 33878776
Drug: Uterus transplantation
RxNorm normalized name: Oryctolagus cuniculus uterus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterus transplantation with immunosuppressive therapy
Trial: 33879263
Drug: Azithromycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (single directly observed dose)
Trial: 33879458
Drug: IMU-131 (B-cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMU-131 (B-cell epitope vaccine)
Trial: 33879458
Drug: C3 cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C3 cohort (50 μg dose)
Trial: 33879458
Drug: C1 and
RxNorm normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 and C2 cohorts (10 and 30 μg doses)
Trial: 33879515
Drug: Insulin-induced blood
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-induced blood glucose normalization (from 7.6±0.4 mmol/L to 4.5±0.07 mmol/L for 1 hour)
Trial: 33879515
Drug: Insulin-induced blood
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-induced blood glucose normalization
Trial: 33879515
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group maintained at 4.9±0.1 mmol/L
Trial: 33879601
Drug: pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 2 mg/kg every 3 weeks for ≤2 years
Trial: 33879601
Drug: salvage therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salvage therapies including chemotherapies and immunotherapies
Trial: 33879722
Drug: Aggressive hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive hydration with Lactated Ringer Solution
Trial: 33880438
Drug: Intensive Therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive Therapy Unit (ITU) workers
Trial: 33880555
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg respectively, intravenously every 3 weeks ×4, followed by nivolumab 3 mg/kg every 2 weeks until progression, unacceptable toxicity, or 24 months)
Trial: 33880939
Drug: Sufentanil sublingual
RxNorm normalized name: SUFentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil sublingual tablet analgesia